Search
for

    Glossary Cetuximab

    monoclonal antibody used to treat certain cancers by targeting EGFR

    Cetuximab, also known by the brand name Erbitux, is a monoclonal antibody used in cancer treatment. It works by targeting the epidermal growth factor receptor (EGFR) on the surface of cancer cells, inhibiting their growth and survival. This drug is commonly used to treat certain types of head, neck, and colorectal cancers.

    Research 10 of 171

    1. Trichomegaly of the eyelashes following treatment with cetuximab Annals of oncology · 2005 · 78 citations
    2. Efficacy and Skin Toxicity Management with Cetuximab in Metastatic Colorectal Cancer: Outcomes from an Oncologic/Dermatologic Cooperation Clinical colorectal cancer · 2008 · 42 citations
    3. Fatal Toxic Epidermal Necrolysis Associated With Cetuximab in a Patient With Colon Cancer Journal of Clinical Oncology · 2008 · 35 citations
    4. Cetuximab-Associated Elongation of the Eyelashes American Journal of Clinical Dermatology · 2010 · 30 citations
    5. Incidence and management of cutaneous toxicities associated with cetuximab Expert opinion on drug safety · 2007 · 30 citations
    6. Cetuximab-induced hypertrichosis of the scalp and eyelashes Journal of The American Academy of Dermatology · 2010 · 12 citations
    7. Adverse Reaction to Cetuximab, an Epidermal Growth Factor Receptor Inhibitor. PubMed · 2016 · 5 citations
    8. Hypertrichosis, trichomegaly, and androgenic alopecia related to cetuximab treatment Journal of Cancer Research and Therapeutics · 2019 · 3 citations
    9. Cetuximab Induced Hidrocystomas: A Case Report SKIN The Journal of Cutaneous Medicine · 2020
    10. Response of Cutaneous Squamous Cell Carcinoma to Treatment With Cetuximab Dermatologic Surgery · 2018 · 1 citations
    All research results →

    Learn

    — no results

    Try a deeper search in learn →

    Community

    — no results

    Try a deeper search in community →